Raymond James Keeps Market Perform on Korro Bio as Preclinical Data and Cash Position Draw Scrutiny
Raymond James has reaffirmed a Market Perform rating on Korro Bio Inc. (NASDAQ:KRRO). The research note cited preclinical evidence for the company’s lead program, KRRO-121, alongside patient anecdotes highlighting the burden of urea cycle disorders (UCD). Korro’s shares trade at $10.74 with a market capitalization of $101.14 million and show mixed …